Cargando…
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates
The development of immunogens that elicit broadly reactive neutralising antibodies (bNAbs) is the highest priority for an HIV vaccine. We have shown that a prime-boost vaccination strategy with vaccinia virus expressing the envelope glycoprotein gp120 of HIV-2 and a polypeptide comprising the envelo...
Autores principales: | Taveira, Nuno, Figueiredo, Inês, Calado, Rita, Martin, Francisco, Bártolo, Inês, Marcelino, José M., Borrego, Pedro, Cardoso, Fernando, Barroso, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219247/ https://www.ncbi.nlm.nih.gov/pubmed/37240423 http://dx.doi.org/10.3390/ijms24109077 |
Ejemplares similares
-
Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection
por: Barroso, Helena, et al.
Publicado: (2011) -
A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies
por: Calado, Rita, et al.
Publicado: (2020) -
Origin and Epidemiological History of HIV-1 CRF14_BG
por: Bártolo, Inês, et al.
Publicado: (2011) -
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals
por: Martin, Francisco, et al.
Publicado: (2022) -
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds
por: Moranguinho, Inês, et al.
Publicado: (2023)